Difference between revisions of "Renal cell carcinoma, VHL-associated"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="float:right; margin-left: 5px;" |- |back to top |}" to "") |
||
| Line 10: | Line 10: | ||
=All lines of therapy= | =All lines of therapy= | ||
==Belzutifan monotherapy {{#subobject:egac3f|Regimen=1}}== | ==Belzutifan monotherapy {{#subobject:egac3f|Regimen=1}}== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
===Regimen {{#subobject:py42s1|Variant=1}}=== | ===Regimen {{#subobject:py42s1|Variant=1}}=== | ||
{| class="wikitable" style="width: 60%; text-align:center;" | {| class="wikitable" style="width: 60%; text-align:center;" | ||
Revision as of 11:19, 26 July 2022
Section editor transclusions Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Belzutifan monotherapy
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Jonasch et al. 2021 (MK-6482-004) | 2018-2019 | Phase 2 (RT) |
Targeted therapy
- Belzutifan (Welireg) 120 mg PO once per day
Continued indefinitely
References
- MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains verified protocol Pubmed NCT03401788